This is a multicenter observational study with a retrospective and a prospective cohort investigating clinically and biologically the APL-like subset as a potential predictor of coagulopathy and susceptibility to early vascular events.
Patients with de novo AML, untreated, newly diagnosed, according to WHO/ICC 2022 criteria from January 2015 onwards.
Presence of NPM1 mutation.
Availability of immunophenotypic characterization at diagnosis
Age >= 18 years
No specific exclusion criteria are provided once eligibility criteria are met.